

PeriVision registers VR- & AI-based eye testing platform VisionOne with US FDA

Lausanne, Switzerland – March 10, 2024.

[PeriVision](#), an innovative spin-off from the University of Bern and the University Hospital Bern, proudly announces its recent FDA registration for its first medical software product VisionOne. This significant milestone marks a pivotal moment in PeriVision's mission to enhance patient care and revolutionize the field of ophthalmology. With VisionOne, ophthalmologists and optometrists can easily configure eye tests on portable VR headsets and subsequently analyze the results on a cloud platform. In the back-end AI algorithms optimize the eye tests, automate assistance, control quality and provide valuable insights for clinical decisions.

The FDA registration underscores PeriVision's commitment to meeting the highest standards of safety, efficacy, and quality in its medical software according to Dr. Ernest Cavin, a PeriVision board member with a long career in ophthalmology, most recently as CEO of Haag-Streit USA.

"We are thrilled to receive FDA registration for our latest medical device," said Dr. Ernest Cavin. "This milestone represents the culmination of years of research, development, and collaboration with leading institutions. We are confident that this technology will significantly impact the way eye tests are performed, ultimately improving patient outcomes."



Picture: VisionOne being used in ophthalmology practice Genève Ophtalmologie, Geneva, Switzerland.



PeriVision's FDA-registered device combines cutting-edge technologies such as AI, VR and eye tracking to address the needs of ophthalmologists, optometrists and their patients. PeriVision's first product addresses the unmet clinical need for more efficient visual field testing, a routine eye test for glaucoma diagnosis and monitoring. With over 80 million living with the disease, glaucoma is the leading cause of irreversible blindness globally. Dr. Kevin Gillmann, PeriVision's Chief Medical Officer and a glaucoma specialist himself, emphasizes that this market registration is the starting point on a longer-term roadmap.

“We want to develop a holistic platform comprising a portfolio of eye tests and AI tools to assist ophthalmologists and optometrists in their daily work. Our ultimate goal is to build software tools that improve patient experience, disease management and clinic productivity.”

With its approval, healthcare providers can now confidently integrate this innovative solution into their practice, offering patients access to state-of-the-art care. PeriVision will exhibit its product at the Vision Expo East in New York from March 15 to 17, 2024 (booth F2348). For more information about PeriVision and its FDA-registered medical software system, please visit www.perivision.com or contact info@perivision.com.